These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 32366905)

  • 1. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
    Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
    Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
    Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
    Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supercharging BRD4 with NUT in carcinoma.
    Eagen KP; French CA
    Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
    Wang R; You J
    J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.
    Wang R; Liu W; Helfer CM; Bradner JE; Hornick JL; Janicki SM; French CA; You J
    Cancer Res; 2014 Jun; 74(12):3332-43. PubMed ID: 24736545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.
    Grayson AR; Walsh EM; Cameron MJ; Godec J; Ashworth T; Ambrose JM; Aserlind AB; Wang H; Evan G; Kluk MJ; Bradner JE; Aster JC; French CA
    Oncogene; 2014 Mar; 33(13):1736-1742. PubMed ID: 23604113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is.
    Liao S; Maertens O; Cichowski K; Elledge SJ
    Genes Dev; 2018 Sep; 32(17-18):1188-1200. PubMed ID: 30135075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
    Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
    Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
    Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
    Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Utility of NUT gene expression and rearrangement in diagnosis of NUT midline carcinoma in upper respiratory tract].
    Fang W; French CA; Cameron MJ; Han YD; Liu HG
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):519-24. PubMed ID: 23157742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
    Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
    Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of NUT midline carcinoma.
    French CA
    Annu Rev Pathol; 2012; 7():247-65. PubMed ID: 22017582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
    French CA; Rahman S; Walsh EM; Kühnle S; Grayson AR; Lemieux ME; Grunfeld N; Rubin BP; Antonescu CR; Zhang S; Venkatramani R; Dal Cin P; Howley PM
    Cancer Discov; 2014 Aug; 4(8):928-41. PubMed ID: 24875858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains.
    Alekseyenko AA; Walsh EM; Wang X; Grayson AR; Hsi PT; Kharchenko PV; Kuroda MI; French CA
    Genes Dev; 2015 Jul; 29(14):1507-23. PubMed ID: 26220994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of diagnosing NUT midline carcinoma.
    French CA
    Head Neck Pathol; 2013 Mar; 7(1):11-6. PubMed ID: 23463074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism.
    Shiota H; Elya JE; Alekseyenko AA; Chou PM; Gorman SA; Barbash O; Becht K; Danga K; Kuroda MI; Nardi V; French CA
    Mol Cancer Res; 2018 Dec; 16(12):1826-1833. PubMed ID: 30139738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.
    Yan J; Diaz J; Jiao J; Wang R; You J
    J Biol Chem; 2011 Aug; 286(31):27663-75. PubMed ID: 21652721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.
    Yan Y; Ma J; Wang D; Lin D; Pang X; Wang S; Zhao Y; Shi L; Xue H; Pan Y; Zhang J; Wahlestedt C; Giles FJ; Chen Y; Gleave ME; Collins CC; Ye D; Wang Y; Huang H
    EMBO Mol Med; 2019 Nov; 11(11):e10659. PubMed ID: 31559706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.